These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
54 related articles for article (PubMed ID: 1936485)
1. BIGPRO (biguanides and the prevention of the risk of obesity): study design. A randomized trial of metformin versus placebo in the correction of the metabolic abnormalities associated with insulin resistance. Fontbonne A; André P; Eschwège E Diabete Metab; 1991 May; 17(1 Pt 2):249-54. PubMed ID: 1936485 [TBL] [Abstract][Full Text] [Related]
2. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial. Fontbonne A; Diouf I; Baccara-Dinet M; Eschwege E; Charles MA Diabetes Metab; 2009 Nov; 35(5):385-91. PubMed ID: 19665415 [TBL] [Abstract][Full Text] [Related]
3. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Trolle B; Flyvbjerg A; Kesmodel U; Lauszus FF Hum Reprod; 2007 Nov; 22(11):2967-73. PubMed ID: 17766923 [TBL] [Abstract][Full Text] [Related]
5. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. Chou KH; von Eye Corleta H; Capp E; Spritzer PM Horm Metab Res; 2003 Feb; 35(2):86-91. PubMed ID: 12734787 [TBL] [Abstract][Full Text] [Related]
6. A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. Kohli R; Shevitz A; Gorbach S; Wanke C HIV Med; 2007 Oct; 8(7):420-6. PubMed ID: 17760733 [TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Bugianesi E; Gentilcore E; Manini R; Natale S; Vanni E; Villanova N; David E; Rizzetto M; Marchesini G Am J Gastroenterol; 2005 May; 100(5):1082-90. PubMed ID: 15842582 [TBL] [Abstract][Full Text] [Related]
8. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Fontbonne A; Charles MA; Juhan-Vague I; Bard JM; André P; Isnard F; Cohen JM; Grandmottet P; Vague P; Safar ME; Eschwège E Diabetes Care; 1996 Sep; 19(9):920-6. PubMed ID: 8875083 [TBL] [Abstract][Full Text] [Related]
9. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Kay JP; Alemzadeh R; Langley G; D'Angelo L; Smith P; Holshouser S Metabolism; 2001 Dec; 50(12):1457-61. PubMed ID: 11735093 [TBL] [Abstract][Full Text] [Related]
10. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Glueck CJ; Fontaine RN; Wang P; Subbiah MT; Weber K; Illig E; Streicher P; Sieve-Smith L; Tracy TM; Lang JE; McCullough P Metabolism; 2001 Jul; 50(7):856-61. PubMed ID: 11436194 [TBL] [Abstract][Full Text] [Related]
11. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Tang T; Glanville J; Hayden CJ; White D; Barth JH; Balen AH Hum Reprod; 2006 Jan; 21(1):80-9. PubMed ID: 16199429 [TBL] [Abstract][Full Text] [Related]
12. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Chazova I; Almazov VA; Shlyakhto E Diabetes Obes Metab; 2006 Jul; 8(4):456-65. PubMed ID: 16776753 [TBL] [Abstract][Full Text] [Related]
13. Effect of orlistat on cardiovascular disease risk in obese adults. Swinburn BA; Carey D; Hills AP; Hooper M; Marks S; Proietto J; Strauss BJ; Sullivan D; Welborn TA; Caterson ID Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142 [TBL] [Abstract][Full Text] [Related]
14. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Salpeter SR; Buckley NS; Kahn JA; Salpeter EE Am J Med; 2008 Feb; 121(2):149-157.e2. PubMed ID: 18261504 [TBL] [Abstract][Full Text] [Related]
15. Central obesity, the metabolic syndrome, and plasminogen activator inhibitor-1 in young adults. Appel SJ; Harrell JS; Davenport ML J Am Acad Nurse Pract; 2005 Dec; 17(12):535-41. PubMed ID: 16293162 [TBL] [Abstract][Full Text] [Related]
16. Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes. Jones MR; Mudaliar S; Hernandez-Triana E; Unnikrishnan AG; Lai YL; Abby SL; Misir S; Jin X; Nagendran S Curr Med Res Opin; 2009 Sep; 25(9):2239-49. PubMed ID: 19622007 [TBL] [Abstract][Full Text] [Related]
17. An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet. Glueck CJ; Goldenberg N; Sieve L; Wang P Metabolism; 2008 Jul; 57(7):954-60. PubMed ID: 18555837 [TBL] [Abstract][Full Text] [Related]
18. Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Burgert TS; Duran EJ; Goldberg-Gell R; Dziura J; Yeckel CW; Katz S; Tamborlane WV; Caprio S Pediatr Diabetes; 2008 Dec; 9(6):567-76. PubMed ID: 18761646 [TBL] [Abstract][Full Text] [Related]
19. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus. Ponssen HH; Elte JW; Lehert P; Schouten JP; Bets D Clin Ther; 2000 Jun; 22(6):709-18. PubMed ID: 10929918 [TBL] [Abstract][Full Text] [Related]
20. Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial. Charles MA; Eschwège E; Grandmottet P; Isnard F; Cohen JM; Bensoussan JL; Berche H; Chapiro O; André P; Vague P; Juhan-Vague I; Bard JM; Safar M Diabetes Metab Res Rev; 2000; 16(1):2-7. PubMed ID: 10707032 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]